⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
JNJ News
Johnson & Johnson
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ
globenewswire.com
JNJ
Targeted Drug Delivery Market Size, Share, Trends, and Global Forecast, 2026-2036 | $57.5 Billion Opportunity Fueled by ADCs, LNPs, and 16.5% CAGR
globenewswire.com
PFE
GILD
ABBV
JNJ
ALNY
ARWR
IONS
MRNA
BNTX
HALO
ADCT
AZN
REGN
China Hospital Supplies - Market Size, Share, Trends, and Growth Forecasts (2026-2031) | Market to Reach USD 21.83 Billion as Hospital Expansion Drives 8.41% CAGR
globenewswire.com
MMM
BAX
BDX
BSX
CAH
MDT
JNJ
SNN
STRL
Global Insulated-Gate Bipolar Transistors (IGBT) Market Size and Forecast, 2026-2032 | Electrification Drives 6.51% CAGR and a USD 11.53 Billion Opportunity
globenewswire.com
ON
ADI
NXPI
MPWR
LITE
MI
VSH
TXN
MCHP
AMD
INTC
NVDA
AMAT
KLAC
MU
STM
IRTC
CDNS
SNPS
AEHR
TER
DLTR
ROST
BBY
CVS
KR
WMT
HD
LOW
TGT
COST
PEP
KO
MCD
SBUX
CMG
TSLA
GE
ABBV
AMGN
GILD
BMY
MRK
PFE
JNJ
XOM
CVX
SHEL
T
VZ
TMUS
QCOM
MRVL
LRCX
ASML
INFY
IBM
MSFT
GOOGL
AMZN
META
ORCL
CRM
SAP
ADBE
NFLX
DIS
CMCSA
Johnson & Johnson to Host Enterprise Business Review
businesswire.com
JNJ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ
accessnewswire.com
JNJ
Global Orphan Drugs Market Size, Share and Trends Analysis Report, 2026-2033 | Market to Reach USD 434.9 Billion as Gene and Cell Therapies Drive 9.0% CAGR
globenewswire.com
JNJ
AZN
NVS
VRTX
SNY
AMGN
MRK
BMY
PFE
High-Temperature Superconductor Wires Market - Global Forecast 2026-2032 | Grid Modernization and Fusion Demand Drive 9.83% CAGR to USD 1.68 Billion by 2032
globenewswire.com
AMSC
GE
BRK.A
IBM
AMAT
NVDA
GOOG
MSFT
INTC
AMD
MU
TER
ADI
TXN
ON
NXPI
QCOM
MRVL
SNPS
CDNS
LRCX
KLAC
ASML
PLAB
AMGN
GILD
BMY
PFE
MRK
JNJ
BIIB
REGN
VRTX
MDLZ
BA
LMT
RTX
GD
HII
XOM
CVX
NEE
DUK
SO
AEP
ED
PCG
SRE
XEL
WEC
ETR
NI
D
CMS
PNW
ES
CEG
EXC
EIX
NRG
BWXT
SPWR
FSLR
ENPH
SEDG
PLUG
BALL
AMZN
GOOGL
ROK
HON
ETN
CPRI
V
MA
PYPL
AVGO
CRSP
EDIT
NTLA
ALGN
ISRG
TDOC
BABA
JD
NTES
SMCI
DELL
HPQ
CSCO
Subcutaneous RYBREVANT®▼ (amivantamab) demonstrates 77% overall response rate in first-line treatment of patients with certain types of advanced head and neck cancer
globenewswire.com
JNJ
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer
prnewswire.com
JNJ